Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human

doi:10.1186/1742-4690-4-18

Retrovirology

Volume 4

Viewing options:

Abstract
Full text
PDF (1.9MB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Gillet N
Florins A
Boxus M
Burteau C
Nigro A
Vandermeers F
Balon H
Bouzar AB
Defoiche J
Burny A
Reichert M
Kettmann R
Willems L

on PubMed

Gillet N
Florins A
Boxus M
Burteau C
Nigro A
Vandermeers F
Balon H
Bouzar AB
Defoiche J
Burny A
Reichert M
Kettmann R
Willems L
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Review

Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human

Nicolas Gillet¹ , Arnaud Florins¹ , Mathieu Boxus¹ , Catherine Burteau¹ , Annamaria Nigro¹ , Fabian Vandermeers¹ , Hervé Balon¹ , Amel-Baya Bouzar¹ , Julien Defoiche¹ , Arsène Burny¹ , Michal Reichert² , Richard Kettmann¹ and Luc Willems¹^,3

¹Molecular and Cellular Biology, Faculté Universitaire des Sciences Agronomiques, Gembloux, Belgium

²National Veterinary Research Institute, Pulawy, Poland

³Luc Willems, National fund for Scientific Research, Molecular and Cellular Biology laboratory, 13 avenue Maréchal Juin, 5030 Gembloux, Belgium

author email corresponding author email

Retrovirology 2007, 4:18doi:10.1186/1742-4690-4-18


Published:	16 March 2007

Abstract

In 1871, the observation of yellowish nodules in the enlarged spleen of a cow was considered to be the first reported case of bovine leukemia. The etiological agent of this lymphoproliferative disease, bovine leukemia virus (BLV), belongs to the deltaretrovirus genus which also includes the related human T-lymphotropic virus type 1 (HTLV-1). This review summarizes current knowledge of this viral system, which is important as a model for leukemogenesis. Recently, the BLV model has also cast light onto novel prospects for therapies of HTLV induced diseases, for which no satisfactory treatment exists so far.